1,651 results match your criteria: "McGinty); Johns Hopkins Carey Business School[Affiliation]"

Background: Inflammation and innate immune activation are associated with chronic HIV infection, despite effective treatment. Although gut microbiota alterations are linked to systemic inflammation, the relationships between the gut microbiome, inflammation and HIV remain unclear.

Methods: The UPBEAT-CAD sub-study, examining cardiovascular disease (CVD) risk in HIV, enrolled participants matched on HIV status and traditional CVD risk factors.

View Article and Find Full Text PDF

Objective: Tobacco smoking is the leading cause of preventable death among individuals with serious mental illness (SMI) but few persons with SMI are offered smoking cessation treatment. The purpose of this study was to pilot-test a multicomponent intervention to increase the delivery of evidence-based smoking cessation treatment in community mental health clinics (CMHCs).

Method: This study was carried out at five CMHCs in Maryland involving clinicians who participated in training in smoking cessation.

View Article and Find Full Text PDF

Using the Telomere-to-Telomere reference, we assembled the distribution of simple repeat lengths present in the human genome. Analyzing over two hundred mammalian genomes, we found remarkable consistency in the shape of the distribution across evolutionary epochs. All observed genomes harbor an excess of long repeats, which are prone to developing into repeat expansion disorders.

View Article and Find Full Text PDF

Background: Despite limited scientific evidence, public perceptions of cannabis as health enhancing are significant. As food products, cannabis edibles (edibles), may also leverage food-related associations that convey health. Social media is a prominent and influential source of largely unregulated cannabis information and a potential place to correct misinformation.

View Article and Find Full Text PDF

Objectives: There have been conflicting reports about the frequency of neural autoantibodies in epilepsy cohorts, which is confounded by the lack of clear distinction of epilepsy from acute symptomatic seizures due to encephalitis. The aim of this study was to determine the frequency of neural autoantibodies in a well characterised population of refractory focal epilepsy of known and unknown cause.

Methods: Cases were recruited from epilepsy outpatient clinics at the Princess Alexandra, Mater, Royal Brisbane and Women's and Cairns Base Hospitals from 2021 - 2023.

View Article and Find Full Text PDF

The endothelin-B receptor (ETR) mediates vasodilation in young women, an effect that is absent in postmenopausal women. We have previously demonstrated that ETR-mediated vasodilation is regulated by estradiol (E) in young women; however, the impact of E on ETR function in postmenopausal women remains unknown. Accordingly, the objective of this study was to test the hypothesis that E exposure restores ETR-mediated dilation in postmenopausal women.

View Article and Find Full Text PDF

In-stent restenosis represents a major cause of failure of percutaneous coronary intervention with drug-eluting stent implantation. Computational multiscale models have recently emerged as powerful tools for investigating the mechanobiological mechanisms underlying vascular adaptation processes during in-stent restenosis. However, to date, the interplay between intervention-induced inflammation, drug delivery and drug retention has been under-investigated.

View Article and Find Full Text PDF

Objective: Intimate partner violence (IPV) affects an estimated 47% of women living in the USA in their lifetime and is associated with increased risk of physical and mental health concerns. Current prevention efforts focus on individual and family-level interventions rather than macrosystem-level policies. Thus, we sought to test the effects of Medicaid expansion on the rates of IPV and violence more broadly.

View Article and Find Full Text PDF

Climate change is the greatest threat to human existence. Currently it impacts breast cancer care by disrupting treatment, by food poverty and economic hardship and through fossil fuel pollution which increases breast cancer incidence. These impacts are greatest in those already experiencing deprivation.

View Article and Find Full Text PDF
Article Synopsis
  • - Psychotic disorders show differences between sexes in when they start, their symptoms, and how they progress
  • - The early intervention in psychosis approach is the first move towards customized care that addresses the specific needs of individuals based on their stage of illness
  • - Future advancements in personalized psychosis care should integrate knowledge of these sex-specific differences to better tailor treatment programs
View Article and Find Full Text PDF

Background: Until the COVID-19 pandemic, it had not been possible to examine the effect of rapid policy changes surrounding telemental health on patient-reported mental health care access, costs, symptoms, and functioning. Sizable variation in telemental health use by patient race-ethnicity, age, and rurality, and in its adoption across healthcare settings, underscores the need to study equitable dissemination and implementation of high-quality telemental health services in the real world. This protocol describes an explanatory sequential mixed-methods study that aims to examine the effects of state telemental health policy expansion on patient-reported mental health outcomes, as well as the policy-to-practice pathway from the perspectives of state leaders, clinicians, and staff who care for underserved patients.

View Article and Find Full Text PDF

The psychological study of resilience has increasingly underscored the need for children and families to access material and psychological resources to positively adapt to significant stress. Redistributive policies-policies that downwardly reallocate society's social and economic resources-can offer economically disadvantaged families sustained access to these resources and mitigate the harmful impacts of adversity. This conceptual article builds upon and integrates insights from psychological and policy research to develop a unifying multilevel resilience framework, which we call the Social Determinants of Resilience.

View Article and Find Full Text PDF

Launch of the PANC-PALS Consortium.

Lancet Gastroenterol Hepatol

December 2024

Department of Surgery and Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.

View Article and Find Full Text PDF

Introduction: Demonstrating the impact of implementation science presents a new frontier for the field, and operationalizing downstream impact is challenging. The Translational Science Benefits Model (TSBM) offers a new approach for assessing and demonstrating research impact. Here we describe integration of the TSBM into a mentored training network.

View Article and Find Full Text PDF

While federal rulemaking is an essential part of American governance, it is not well understood by researchers and advocates. We surveyed 115 former regulators at the Environmental Protection Agency to understand their views on the kinds of information they valued most and their communication preferences (June-August 2023). Respondents highly valued information about the scope of a problem (96%), legal analysis (97%), technology assessments (96%), and impacts of a proposed rule (99%).

View Article and Find Full Text PDF

A promising drug target, SETDB1, is a dual Kme reader and methyltransferase, which has been implicated in cancer and neurodegenerative disease progression. To help understand the role of the triple Tudor domain (3TD) of SETDB1, its Kme reader, we first identified a low micromolar small molecule ligand, UNC6535, which occupies simultaneously both the TD2 and TD3 reader binding sites. Further optimization led to the discovery of UNC10013, the first covalent 3TD ligand targeting Cys385 of SETDB1.

View Article and Find Full Text PDF

Target trial emulation is an approach to designing rigorous nonexperimental studies by "emulating" key features of a clinical trial. Most commonly used outside of policy contexts, this approach is also valuable for policy evaluation as policies typically are not randomly assigned. In this article, we discuss the application of the target trial emulation framework in a policy evaluation context.

View Article and Find Full Text PDF

Vascular dysfunction, marked by lower endothelial function and increased aortic stiffness, is a nontraditional risk factor that precedes the development of cardiovascular disease (CVD). However, the age at which these changes in vascular function occur in women and the degree to which reproductive hormones mediate these changes has not been characterized. Women free from major disease were enrolled across the adult life span (aged 18-70 yr, = 140).

View Article and Find Full Text PDF

Several pseudolesions mimicking malignancy have been reported in cirrhotic and non-cirrhotic livers. Pericholecystic regeneration is among those pseudolesions and can occasionally mimic malignancy. Herein we present a case series comprised of 10 cirrhotic patients (majority due to alcoholic liver disease [ALD] or metabolic dysfunction associated steatotic liver disease [MASLD]) with pericholecystic observations initially categorized as highly suspicious for HCC (LR-4 and LR-5) due to their suspicious enhancement pattern which were later proven to be benign based on biopsy, transplantation or imaging criteria (stability of size and morphology on serial CT or MRI for > 2 years).

View Article and Find Full Text PDF

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

N Engl J Med

October 2024

From the Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) - both in the United Kingdom; National Heart Centre Singapore and Duke-National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST "Spedali Civili" Hospital, Brescia (S.N.) - all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) - all in the Netherlands; Université de Lorraine, INSERM Clinical Investigation Centre, Centre Hospitalier Universitaire, Nancy, France (F.Z.); University of Malaya, Kuala Lumpur, Malaysia (I.Z.A.); Centro de Estudios Clínicos de Querétaro, Santiago de Querétaro (M.A.A.-G.), and Hospital Cardiologico Aguascalientes, Aguascalientes (G.L.-E.) - both in Mexico; Cardiology Research Department, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Australia (J.J.A.); the Department of Cardiology and Angiology, Hannover Medical School, Hannover (J.B.), and Bayer, Wuppertal (P.K.) - both in Germany; Beijing Anzhen Hospital, Capital Medical University, Beijing (M.C.-S.); General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital, and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-E.C.); Emergency Institute for Cardiovascular Diseases "Prof. Dr. C.C. Iliescu," University of Medicine Carol Davila, Bucharest, Romania (O.C.); Clinical Cardiology, Heart Failure and Research, Max Super Specialty Hospital, New Delhi, India (V.C.); the Department of Cardiology, Bellvitge University Hospital, and Bellvitge Biomedical Research Institute, Centro de Investigación Biomédica En Red Enfermedades Cardiovasculares, University of Barcelona, L'Hospitalet de Llobregat, Barcelona (J.C.-C.); the Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens (G.F.); the Department of Internal Medicine, Hospital São Francisco Xavier, and NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal (C.F.); the Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Krakow, Poland (G.G.); the Heart Institute, Kaplan Medical Center, Rehovot, and Hebrew University, Jerusalem - both in Israel (S.G.); the Faculty of Medicine, Comenius University, Bratislava, Slovakia (E.G.); the Division of Cardiology, Severance Hospital, and Yonsei University Health System, Seoul, South Korea (S.K.); the Department of Noninvasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.); St. Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (M.N.K.); Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia (G.L.); Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong (A.P.-W.L.); University Clinic of Lomonosov Moscow State University, Moscow (V. Mareev); Universidad Nacional de Córdoba, Córdoba, Argentina (F.A.M.); the Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V. Melenovský); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Centro Cardiovascular Colombiano, Clínica Santa María, Medellin, Colombia (C.I.S.); Cardiovascular Division, Instituto de Pesquisa Clínica de Campinas, Campinas (J.F.K.S.), and Bayer, São Paulo (F.A.) - both in Brazil; Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan (N.S.); the Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark (M. Schou); the Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore (K.S.); Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand (R.T.); Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital (J.A.U.), University of Toronto (J.A.U., S.V.), and the Division of Cardiac Surgery, St. Michael's Hospital (S.V.), Toronto, and the Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg (S.Z.) - both in Canada; Heart Centre, Turku University Hospital, Turku, Finland (H.U.); the Department of Medicine, University of Minnesota, and Minneapolis VA Health Care System, Minneapolis (O.V.); the Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria (D.L.); National Scientific Center, Strazhesko Institute of Cardiology, National Academy of Medical Sciences, Kyiv, Ukraine (L.V.); Dokuz Eylul University Medical Faculty, Cardiology Department, Izmir, Turkey (M.B.Y.); and Bayer, Whippany, NJ (P.V.).

Article Synopsis
  • Steroidal mineralocorticoid receptor antagonists help patients with heart failure and reduced ejection fraction, but their effectiveness in those with mildly reduced or preserved ejection fraction is unclear, indicating a need for further research on finerenone.
  • In a double-blind study, patients with heart failure (ejection fraction 40% or greater) were assigned to receive either finerenone or a placebo to assess its impact on heart failure events and cardiovascular death.
  • Results showed that finerenone led to fewer worsening heart failure events and a lower overall rate of primary outcome events compared to placebo, although it also carried a higher risk of hyperkalemia.
View Article and Find Full Text PDF

Asundexian versus Apixaban in Patients with Atrial Fibrillation.

N Engl J Med

January 2025

From Duke Clinical Research Institute, Duke University School of Medicine (J.P.P., M.R.P., R.D.L., W.S.J., J. Harrington, S.J.E., F.W.R., J.H.A.), and Duke University Medical Center (J.P.P., M.R.P., R.D.L., W.S.J., J. Harrington, F.W.R., J.H.A.) - both in Durham, NC; Hirslanden Clinic Zurich, Zurich, Switzerland (J.S.); the School of Medicine, Tulane University, New Orleans (K.F.); the University Medical Center, University of Groningen, Groningen (I.C.V.G., M.R.), Radboud University Medical Center, Nijmegen (M.H.), Rijnstate Hospital, Arnhem (M.H.), and the Dutch Network for Cardiovascular Research, Utrecht (M.H.) - all in the Netherlands; Cooper Medical School of Rowan University, Camden (A.M.R.), and Bayer U.S., Whippany (R.C.) - both in New Jersey; the Cardiology Center of Beijing, Anzhen Hospital No. 2, Beijing (C.-S.M.); the Canadian VIGOUR Centre, University of Alberta, Edmonton, and St. Michael's Hospital, Unity Health Toronto, and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto - all in Canada (S.G.G.); the Uppsala Clinical Research Center and the Department of Medical Sciences, Uppsala University, Uppsala, Sweden (J.O.); the Department of Cardiology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia (C.H.); the Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan (M.A.); the School of Cardiology, University of Pisa, and the Cardiology Division, Pisa University Hospital, Pisa (R.D.C.), and Santa Maria della Misericordia Hospital, University of Perugia, Perugia (V.C.) - all in Italy; the Department of Cardiology, University Heart and Vascular Center Hamburg, and the German Center for Cardiovascular Research, Hamburg (P.K.), and Bayer, Wuppertal (C.N., T.V., H.M.) - all in Germany; the Institute of Cardiovascular Sciences, University of Birmingham, Birmingham (P.K.), the Faculty of Medicine, National Heart and Lung Institute, Imperial College, London (D.A.G.), the Centre for Health Services and Clinical Research, Faculty of Life and Medical Sciences, University of Hertfordshire, Hatfield (D.A.G.), and the Liverpool Centre for Cardiovascular Science at University of Liverpool and John Moores University and Liverpool Heart and Chest Hospital, Liverpool (G.Y.H.L.) - all in the United Kingdom; the Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark (G.Y.H.L.); and Bayer, São Paulo (J. Hung).

Background: Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibitor, is an oral anticoagulant that may prevent strokes with less bleeding.

Methods: In a phase 3, international, double-blind trial, we randomly assigned high-risk patients with atrial fibrillation in a 1:1 ratio to receive asundexian at a dose of 50 mg once daily or standard-dose apixaban.

View Article and Find Full Text PDF